InMed Pharmaceuticals
Global leader in the manufacturing and development of rare cannabinoids. Our subsidiary is Baymedica. Nasdaq: $INM
Global leader in the manufacturing and development of rare cannabinoids. Our subsidiary is Baymedica. Nasdaq: $INM
InMed Pharmaceuticals, a pharmaceutical company founded in 1981, is dedicated to developing small molecule drug candidates targeting the CB1/CB2 receptors. The company's pipeline comprises three drug development programs focusing on Alzheimer's, ocular, and dermatological indications. In collaboration with its subsidiary BayMedica, InMed Pharmaceuticals is a global leader in the manufacturing, development, and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. The company's notable milestone was a Post-IPO Equity investment on 18 November 2022. InMed Pharmaceuticals is listed on Nasdaq under the symbol INM. For more information, visit www.inmedpharma.com. The company operates in the biotechnology, health care, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | Unknown | - | 18 Nov 2022 | |
| Post-IPO Equity | Unknown | - | 09 Sep 2022 | |
| Post-IPO Equity | Unknown | - | 02 Jun 2022 | |
| Post-IPO Equity | Unknown | - | 29 Jun 2021 | |
| Post-IPO Equity | Unknown | - | 05 Feb 2021 |
No recent news or press coverage available for InMed Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
